ProSomnus (ProSomnus) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is ProSomnus Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of ProSomnus is: No Data: Cannot be evaluated.

Competitive Comparison of ProSomnus's Risk Assessment

For the Medical Devices subindustry, ProSomnus's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProSomnus's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ProSomnus's Risk Assessment distribution charts can be found below:

* The bar in red indicates where ProSomnus's Risk Assessment falls into.

ProSomnus (OTCPK:OSAPQ) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

ProSomnus Risk Assessment Related Terms

Thank you for viewing the detailed overview of ProSomnus's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

ProSomnus (ProSomnus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ProSomnus Inc (OTCPK:OSAPQ) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

5675 Gibraltar Drive, Pleasanton, CA, USA, 94588

Website

https://www.prosomnus.com

ProSomnus Inc is a medical device manufacturer. It manufacturers precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea, which affects over 74 million Americans and is associated with serious comorbidities, including heart failure, stroke, hypertension, morbid obesity and type 2 diabetes. ProSomnus's patented devices are more comfortable and less invasive alternative to continuous positive airway pressure therapy, and lead to more effective and patient-preferred outcomes.

Executives

Sung Kim	officer: Chief Technical Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
John Steffens	10 percent owner	C/O DIGITALBRIDGE GROUP, INC., 750 PARK OF COMMERCE DRIVE SUITE 210, BOCCA RATON FL 33487
Gregory P. Ho	10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Brian B Dow	officer: Chief Financial Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Smc Holdings Ii, Lp	10 percent owner	65 EAST 55TH STREET, 33RD FLOOR, NEW YORK NY 10022
Smc Holdings Ii G.p., Llc	10 percent owner	C/O SPRING MOUNTAIN CAPITAL, LP, 650 MADISON AVENUE, 20TH FLOOR, NEW YORK NY 10022
Laing Rikkers	director	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Len Liptak	director, officer: Chief Executive Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Mark Thomas Murphy	officer: Chief Growth Officer	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588
Hgp Iii, Llc	10 percent owner	3708 ASHFORD PLACE, GREENVILLE NC 27858
Steven Robert Pacelli	director	5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Hmc, Llc	10 percent owner	3708 ASHFORD PLACE, GREENVILLE NC 27858
Healthpointcapital, Llc	10 percent owner	C/O HEALTHPOINTCAPITAL, 505 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Healthpointcapital Partners Iii Lp	10 percent owner	505 Park Avenue, 12th Floor, New York NY 10022
Leonard Hedge	director	7855 BELLA MONTANIA LANE, PALO CEDRO CA 96073